Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. - Sockel K; Bornhaeuser M; Mischak-Weissinger E; Trenschel R; Wermke M; Unzicker C; Kobbe G; Finke J; Germing U; Mohr B; Greiner J; Beelen D; et al. (Haematologica, 2012)